Stay updated on Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial page.

Latest updates to the Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial page
- CheckyesterdayChange DetectedThe listed study count increased from 604,566 to 605,599, while the geographic coverage remained the same.SummaryDifference0.1%

- Check8 days agoChange DetectedOn the homepage, the text now specifies that ClinicalTrials.gov covers 604,566 studies and spans all 50 states and 226 countries and territories. This replaces the earlier incomplete line, clarifying the scope of studies accessible through the site.SummaryDifference0.1%

- Check15 days agoChange DetectedThe exact count of studies text was replaced with a generic statement about ClinicalTrials.gov covering locations across all 50 states and countries, and the release version was updated from v3.6.6 to v3.7.0.SummaryDifference0.3%

- Check22 days agoChange DetectedThe homepage now shows 602,520 studies, up from 601,694, reflecting an expansion in the registered studies listed on the site.SummaryDifference0.1%

- Check29 days agoChange DetectedThe homepage text was updated to show 601,694 studies across all 50 states and 226 countries and territories, replacing the previous figure of 600,762. This reflects the current size of the ClinicalTrials.gov database.SummaryDifference0.1%

- Check36 days agoChange DetectedClinicalTrials.gov is a place to learn about 600,762 studies with locations in all 50 states and in 226 countries and territories, up from 599,765. The site revision has been updated to v3.6.6 (from v3.6.5).SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial page.